DTIL
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company\'s pipeline consists of multiple \'off-the-shelf\' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.
Precision BioSciences, Inc. (DTIL) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Profitability (C). The rating has held at C+ for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.8) | B (3.2) | C (2.4) | B- (3.0) | C+ (2.6) | C+ (2.8) |
| 2026-11-04 | B- (3.0) | C (2.3) | C (2.5) | C (2.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-28 | B- (3.0) | C (2.2) | C (2.5) | C (2.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-21 | B- (3.0) | C (2.2) | C (2.5) | C (2.3) | C+ (2.6) | C+ (2.5) |
| 2026-10-14 | B- (3.0) | C (2.2) | C (2.5) | C- (2.1) | C+ (2.6) | C (2.5) |